Mablink confirms agreement to be acquired by Lilly

19 October 2023
lilly_big

French pre-clinical biotech Mablink Biosciences has confirmed earlier rumors that it has agreed to a takeover bid from acquisition-hungry US pharma major Eli Lilly (NYSE: LLY).

The transaction, financial terms of which were not disclosed, is subject to approval from the French Ministry of the Economy. It also marks the sixth M&A deal this year by Lilly.

Lyon-based Mablink is building a pipeline on PSARLink, a linker technology designed to reduce systemic toxicity and increase the amount of the therapeutic payload delivered to target cancer cells.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology